To include your compound in the COVID-19 Resource Center, submit it here.

Stakeholders warn of over-reliance on Chinese APIs

Multiple speakers at a hearing on U.S. use of China biotech supplies this week warned that relying on the country's supplies and services threatens the U.S. drug supply, consumer safety and personal health data.

“The national security risks of increased Chinese dominance of the global API market cannot be overstated,” Christopher Priest, deputy director of health operations at

Read the full 584 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers